Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 192 HKD -0.88% Market Closed
Market Cap: 261.6B HKD

Beigene Ltd
Interest Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Beigene Ltd
Interest Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Expense CAGR 3Y CAGR 5Y CAGR 10Y
Beigene Ltd
HKEX:6160
Interest Expense
ÂĄ175m
CAGR 3-Years
-6%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Interest Expense
ÂĄ68.3m
CAGR 3-Years
88%
CAGR 5-Years
64%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Interest Expense
ÂĄ139.5m
CAGR 3-Years
25%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Interest Expense
ÂĄ8.3m
CAGR 3-Years
14%
CAGR 5-Years
52%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Interest Expense
ÂĄ3.8m
CAGR 3-Years
-68%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Beigene Ltd
Glance View

Market Cap
274.2B HKD
Industry
Biotechnology

BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.

Intrinsic Value
141.14 HKD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Beigene Ltd's Interest Expense?
Interest Expense
175m CNY

Based on the financial report for Dec 31, 2024, Beigene Ltd's Interest Expense amounts to 175m CNY.

What is Beigene Ltd's Interest Expense growth rate?
Interest Expense CAGR 5Y
15%

Over the last year, the Interest Expense growth was 242%. The average annual Interest Expense growth rates for Beigene Ltd have been -6% over the past three years , 15% over the past five years .

Back to Top